Rival permanent heart implants enter human trials
This article was originally published in Clinica
US company Arrow International last week announced the first clinical implant of its permanent heart replacement device for patients with end-stage heart failure. At the same time, its competitor Abiomed said that it was ready to start human trials of its permanent device, assuming it gets regulatory approval, now that it is producing clinically configured versions of the AbioCor pump.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.